Lilly strikes $7M-plus licensing deal

Eli Lilly and Co. will pay at least $7 million to acquire rights to a diabetes compound developed by Toronto-based Transition Therapeutics Inc., the companies announced tonight.

Indianapolis-based Lilly will work with Transition to complete a Phase II trial of a compound called TT-223, which provided sustained improvement in blood sugar control during preclinical studies.

Under the terms of the agreement, Lilly could pay Transition up to $130 million if the company achieves certain development and sales goals. Transition would also receive royalties from any future commercial sales.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.